Table of contents
- Trial overview
- Who can join the study
- What is being tested
- Study phases and endpoints
- What the study measures
Trial overview
The study with RNK001 is an interventional trial, which means researchers give a treatment and then measure what happens.[1] It is authorised and plans to enroll 16 patients.[1]
The trial title describes it as an infusion of ex vivo-generated allogeneic natural killer cells with subcutaneous IL-2 in patients with acute myeloid leukemia, and the brief summary says it is a phase I/IIa study.[1] In simple words, the study looks at a cell-based treatment approach for people with serious blood cancers.[1]
Who can join the study
The trial is for patients with MDS with excess blasts, MDS/AML, or AML.[1] These conditions are all serious diseases of the blood and bone marrow, the part of the body that makes blood cells.[1]
The source also says the study uses a non-myeloablative immunosuppressive conditioning regimen before the study treatment.[1] This means patients receive a preparation treatment that lowers the immune system, but does not fully destroy the bone marrow.[1]
What is being tested
The study tests RNK001 as an intravenous infusion, and in some parts of the study it is given with subcutaneous IL-2, also called Proleukin in the source data.[1] The trial title also says the treatment uses ex vivo-generated allogeneic natural killer cells, which means donor immune cells made outside the body and then given to the patient.[1]
The brief summary says phase I evaluates the safety and toxicity of ex vivo-expanded RNK001 NK cells, with and without subcutaneous IL-2, after the conditioning regimen.[1] The phase IIa part looks at the effect of RNK001 NK cell adoptive immunotherapy with subcutaneous IL-2 on disease activity.[1]
Study phases and endpoints
This is a phase I/IIa study, so it has two main goals.[1] Phase I is the early safety part, and phase IIa is the early activity part.[1]
For phase I, the main endpoint is safety and toxicity of the RNK001 NK cell infusions, whether or not they are followed by subcutaneous IL-2.[1] The study uses CTCAE toxicity criteria and graft versus host disease (GvHD) classification criteria to define dose limiting toxicities.[1]
For phase IIa, the main endpoint is clinical response to therapy, which will be defined using European Leukemia Network (ELN) response criteria by day +28 after NK cell administration.[1] Day +28 means 28 days after the cells are given.[1]
What the study measures
The study measures whether RNK001 causes harmful effects, called toxicity, during the safety part of the trial.[1] It also checks for dose limiting toxicities, which are side effects that can stop researchers from giving more of the treatment.[1]
Another important safety measure is graft versus host disease, a reaction that can happen when donor immune cells attack the patient’s body.[1] In the later part of the study, researchers look for signs that the treatment changes the disease, using standard leukemia response rules.[1]
Because the study is small and early, it is mainly designed to learn whether this treatment approach is safe enough and whether it shows early signs of benefit in these blood cancers.[1]
